Objectives: Sternal wound infections are serious postoperative complications that increase the length of hospital stay and healthcare costs. The benefit of implantable gentamicin-collagen sponges in reducing sternal wound infections has been questioned in a recent multicenter trial. We aimed to perform a comprehensive metaanalysis of studies assessing the efficacy of implantable gentamicin-collagen sponges in sternal wound infection prevention.
Results: A total of 14 studies (N ¼ 22,135, among them 4 randomized controlled trials [N ¼ 4672]) were included in the analysis. Implantable gentamicin-collagen sponges significantly reduced the risk of sternal wound infection by approximately 40% when compared with control (risk ratio [RR] , 0.61; 95% confidence interval [CI] , 0.39-0.98; P ¼ .04 for randomized controlled trials and RR, 0.61; 95% CI, 0.42-0.89; P ¼ .01 for observational studies). A similar, significant benefit was demonstrated for deep sternal wound infection (RR, 0.60; 95% CI, 0.42-0.88; P ¼ .008) and superficial sternal wound infection (RR, 0.60; 95% CI, 0.43-0.83; P ¼ .002). The overall analysis revealed a reduced risk of mediastinitis (RR, 0.64; 95% CI, 0.45-0.91; P ¼ .01). The risk of death was unchanged. A significant positive linear correlation (P ¼ .05) was found between the log RR of sternal wound infection and the percentage of patients receiving bilateral internal thoracic artery grafts.
Conclusions: Implantable gentamicin-collagen sponges significantly reduce the risk of sternal wound infection after cardiac surgery, with evidence consistent in randomized and observational-level data. However, the extent of this benefit might be attenuated in patients receiving bilateral internal thoracic artery grafts. (J Thorac Cardiovasc Surg 2015;149:1631-40)
Efficacy of implantable gentamicin-collagen sponge in preventing sternal wound infections.
Central Message
Implantable gentamicin-collagen sponge significantly reduces the risk of sternal wound infection after cardiac surgery by nearly 40% with evidence highly consistent in randomized-and observational-level data. However, the extent of this benefit might be attenuated in patients receiving bilateral internal thoracic artery grafts.
Perspective
Recent randomized study introduced substantial uncertainty regarding the efficacy of implantable gentamicin-collagen sponge in sternal wound infections prophylaxis. Present study confirms and corroborates in a systematic fashion the findings from the previous studies showing statistically significant reduction of sternal wound infections in patients in whom gentamicin sponge was implanted. Lower benefit conferred by the gentamicin sponge in patients receiving bilateral internal thoracic artery grafts should direct the surgeon's attention to these patients in particular because other potentially preventive measures must be undertaken in this population.
See Editorial Commentary page 1641. Supplemental material is available online.
Routine intravenous antibiotic prophylaxis initiated before cardiothoracic surgery has been consistently shown to reduce the postoperative rates of infections and in turn associated morbidity and mortality. 1 Sternal wound infections (SWIs) are serious postoperative complications increasing both length of hospital stay and healthcare costs. Several early randomized and observational studies demonstrated implantable gentamicin-collagen sponges (IGCSs) to further reduce (by 33%-62%) the infectious complications compared with intravenous (IV) prophylaxis alone when inserted between sternal halves immediately before closure of the mediastinum. [2] [3] [4] [5] These implants deliver high concentrations of gentamicin locally within the wound, therefore preventing the systemic adverse effects of such high regimens and at the same time lowering the risk of acquired bacterial resistance to antibiotics. 6 On the other hand, the recent SWIPE-1 7 trial questioned those results, showing no extra benefit of IGCS among US patients at high baseline risk, including diabetes, body mass index (BMI)>30 kg/m 2 , or both. The study showed no difference between IGCS and control groups for the outcomes of superficial SWI (SSWI), deep SWI (DSWI), and rehospitalization for wound infection at 90-day follow-up. Driven by the conflicting results and limited number of randomized studies, we aimed to perform an updated and comprehensive metaanalysis of randomized controlled trials (RCTs) with an addition of observational data to further corroborate the obtained results. In addition, for the first time, we try to explore the efficacy of the IGCS in the setting of bilateral internal thoracic artery (BITA) harvest.
MATERIALS AND METHODS Data Sources and Search Strategy
Established methods were used in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement for reporting systematic reviews and meta-analyses in health care interventions. 8 PubMed, EMBASE, CINAHL, Scopus, the Web of Science, the Cochrane Register of Controlled Clinical Trials (CENTRAL), and Congress proceedings from major cardiothoracic and cardiothoracic societies meetings were screened for randomized and observational studies comparing the efficacy of the IGCS in prophylaxis of SWI after cardiac surgery with placebo or no intervention. Search terms were gentamicin collagen sponge, gentamicin implant, gentamicin sponge, cardiac surgery, heart surgery, DSWI, SSWI, and mediastinitis. No language, publication date, or publication status restriction was imposed. Both blinded and open-label trials were considered eligible. The most updated or inclusive data for each study were used for abstraction. References of original and review articles were cross-checked.
Selection Criteria and Quality Assessment
Citations were screened at title/abstract level and retrieved as full reports if they fulfilled the inclusion criteria: (1) human studies; (2) RCTs or observational studies with control group; and (3) prespecified outcome of SWI reported. Two independent reviewers (M.K. and W.P.) selected the studies for the inclusion and extracted studies and patient characteristics of interest and relevant outcomes; divergences were resolved by consensus after discussion with a third reviewer (L.A.). Three authors (M.K., W.P., and M.E.K.) independently assessed the trials' eligibility and risk of bias. The bias risk for randomized studies was assessed using the components recommended by the Cochrane Collaboration, that is, random sequence generation and random allocation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias. 9 The quality of observational studies was appraised with the Newcastle-Ottawa Scale, a tool used for assessing the bias (the selection of the study groups, the comparability of the groups, and the ascertainment of the exposure or outcome of interest) in case-control and cohort studies included in a systematic review or meta-analyses. 10 
Outcome Measures
The primary end point was the occurrence of SWI after cardiac surgery. Secondary end points were the occurrence of DSWI, SSWI, mediastinitis, and mortality. Definitions for the type, degree, and depth of the infection were applied as per study protocol.
Statistical Analysis
Data were analyzed according to the intention-to-treat principle. Randomized and observational studies were assessed separately. Risk ratios (RRs) and 95% confidence intervals (CIs) were used as summary statistics. Heterogeneity was assessed by the Cochran Q test. 11 The statistical inconsistency test was
, where Q is the chi-square statistic and df is its degrees of freedom. Thresholds for the interpretation of I 2 for low, moderate, and considerable degree of heterogeneity were values of 25%, 50%, and 75%, respectively.
12 Pooled RRs were calculated using a fixed-effects model for a randomized trials subset in case of low heterogeneity. Pooled RRs from observational studies were calculated using random-effects model with the Mantel-Haenszel method as the most conservative approach. Potential publication bias was examined for the primary end point constructing a ''funnel plot'' in which the standard error of the log risk ratio (logRR) was plotted against the RR. The asymmetry of the plot was estimated both visually and by a linear regression approach. Random-effects meta-regression analyses accounting for within-and between-study variations were conducted to evaluate linear correlations between the occurrence of any surgical site infection and the percentage of patients in each study receiving BITA and single internal thoracic artery (SITA) grafts, with the sample size as weight. 13 Finally, we addressed the influence of each study and potential publication bias by testing whether deleting each study in turn would have significantly changed the pooled results of the meta-analysis for the
Abbreviations and Acronyms
BITA ¼ bilateral internal thoracic artery BMI ¼ body mass index CI ¼ confidence interval DSWI ¼ deep sternal wound infection IGCS ¼ implantable gentamicin-collagen sponge logRR ¼ log risk ratio RCT ¼ randomized controlled trial RR ¼ risk ratio SSWI ¼ superficial sternal wound infection SWI ¼ sternal wound infection primary end point. Likewise, prespecified sensitivity analyses were also performed after exclusion of studies with high risk of bias, studies available as abstracts only, and studies in which a non-Food and Drug Administration-approved gentamicin sponge was used. To better quantify the contribution of proper, manufacturer-advised sponge placement, the analysis was repeated after exclusion of 4 studies reporting the IGCS to be premoistened in normal saline before implantation. Review Manager 5.1 (The Nordic Cochrane Center, Købehvn, Denmark) and Comprehensive Meta-Analysis, version 2 (Biostat, Englewood, NJ) were used for statistical computations. P values are reported as 2-sided.
RESULTS
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart, describing the process of publication screening and the reasons for exclusion, is shown in Figure 1 . Of 642 potentially relevant reports that were retrieved for scrutiny, 623 were excluded during secondary screening. The remaining 19 underwent thorough assessment based on prespecified eligibility criteria. One study was excluded because 2 different gentamicin sponges (equine and bovine collagen matrix) were compared, 14 and another was excluded because IGCS was given as an addition to intervention for deep sternal wound complications 15 and not as a prophylaxis. Another 2 studies did not report the outcomes of interest.
A total of 14 studies [2] [3] [4] [5] [6] [7] [16] [17] [18] [19] [20] [21] [22] [23] (N ¼ 22,135; among them 4 RCTs [N ¼ 4672]) were eventually included for data abstraction and entered the analysis. All published studies were retrieved as full texts. Congress proceedings abstracts were available as separate reports. The characteristics of included studies stratified by study design are listed in Table 1 .
Among the RCTs, only 1 was multicenter, 7 1 was 2-center, 3 and 2 were conducted in single institutions.
2,16
The study by Schimmer and colleagues 16 was the only one to use a placebo-impregnated sponge, therefore attenuating the allocation concealment bias. Eleven observational studies (N ¼ 18,430) entered the analysis. [4] [5] [6] [16] [17] [18] [19] [20] [21] [22] [23] Study characteristics are listed in Table 1 . Three studies were available as abstracts only. [20] [21] [22] Potential sources of bias according to Newcastle-Ottawa Scale are described in Table E1 .
Sternal Wound Infection Randomized controlled trials. Four studies (N ¼ 4672) were included in the analysis of SWI (Figure 2 , A). The IGCS-based intervention was associated with a significant, approximately 40% risk reduction when compared with (Figure 2, A) . SWIs occurred in 152 of 4520 ICGS-treated patients and 470 of 13,910 controls. Prophylaxis with IGCS was associated with a 39% reduced risk of SWI compared with the control group (RR, 0.61; 95% CI, 0.42-0.89; P ¼ .01; I 2 ¼ 64%). Overall. Pooled together, randomized and observational studies demonstrated the gentamicin-collagen sponge to be associated with a significant 38% reduced risk of SWI (RR, 0.62; 95% CI, 0.47-0.81; P < .001; I 2 ¼ 63%) (Figure 2, A) . Analysis of differences between RCTs and observational studies showed no signs of inconsistency: test for subgroup differences: chi-square ¼ 0.00; P ¼ .99; I 2 ¼ 0%. Regression of logRR against the percentage of patients receiving BITA grafts demonstrated a significant positive correlation (P slope ¼ .05) between the risk of SWI and the extent to which BITA harvest was performed (Figure 2, B) . Analysis regressing the percentage of single ITA against logRR revealed a borderline significant negative correlation (P slope ¼ .06) (Figure 2, C) .
Deep Sternal Wound Infection
Randomized controlled trials. Data on DSWI were available from 4 RCTs; gentamicin sponge prophylaxis reduced the risk of DSWI by 40% compared with the control group (RR, 0.60; 95% CI, 0.42-0.88; P ¼ .008; I 2 ¼ 19%); the corresponding event rates were 43 of 2335 IGCS-treated patients (1.84%) and 71 of 2337 controls (3.04%) (Figure 3, A) . Observational studies. Four observational studies reported on the incidence of DSWI with N ¼ 11,716 patients. A nonsignificant risk reduction was observed with IGCS when compared with the control group (RR, 0.60; 95% CI, 0.32-1.13; P ¼ .12; I 2 ¼ 56%) (Figure 3, A) . Overall. In the overall analysis, gentamicin sponge prophylaxis demonstrated a 38% risk reduction compared with the control group (RR, 0.62; 95% CI, 0.44-0.87; P ¼ .006; I 2 ¼ 34%) (Figure 3, A) . Analysis of differences between RCTs and observational studies showed no signs of inconsistency: test for subgroup differences: chi-square ¼ 0.00; P ¼ .96; I 2 ¼ 0%. Regression of logRR against the percentage of patients receiving BITA grafts demonstrated a significant positive correlation (P slope ¼ .05) between the risk of DSWI and the extent to which BITA harvest was performed (Figure 3, B) . Analysis regressing the percentage of single ITA against logRR revealed a significant negative correlation (P slope ¼ .05) (Figure 3, C) . (Figure 4, A) . Observational studies. In 5 observational studies (N ¼ 3922 patients), data on the incidence of SSWI were available; a significant 45% risk reduction was observed with IGCS when compared with the control group (RR, 0.55; 95% CI, 0.36-0.86; P ¼ .008; I 2 ¼ 66%); event rates were 129 of 2260 (5.71%) and 185 of 1662 (11.13%), respectively (Figure 4, A) . Overall. Pooled together (9 studies), gentamicin sponge prophylaxis demonstrated a significant, 40% risk reduction compared with the control group (RR, 0.60; 95% CI, 0.43-0.83; P ¼ .002; I 2 ¼ 66%) (Figure 4 , A). No signs of inconsistency were found for the comparison between observational and randomized studies; test for subgroup differences: chi-square ¼ 0.15; P ¼ .70; I 2 ¼ 0%. No correlations between the risk of SSWI and the extent to which both BITA and SITA harvest was performed were found by meta-regressions ( Figure 4 , B and C, respectively).
Mediastinitis
Randomized controlled trials. Three RCTs (N ¼ 3212 patients) were available for inclusion in the analysis of mediastinitis; event rates were 18 of 1608 (1.12%) versus 33 of 1604 (2.06%) (RR, 0.50; 95% CI, 0.19-1.33; P ¼ .16; I 2 ¼ 51%) ( Figure E1 ). Observational studies. Six observational studies (N ¼ 7096 patients) contributed to the analysis of mediastinitis; a significant 33% risk reduction was observed with IGCS when compared with the control group (RR, 0.67; 95% CI, 0.45-0.99; P ¼ .04; I 2 ¼ 6%); event rates were 46 of 3841 (1.20%) and 67 of 3255 (2.06%), respectively ( Figure E1 ). Overall. In total, 9 studies were included; gentamicin sponge prophylaxis demonstrated a significant, 36% risk reduction compared with the control group (RR, 0.64; 95% CI, 0.45-0.91; P ¼ .01; I 2 ¼ 16%) ( Figure E1 ). Observational studies were found statistically consistent with RCTs; test for subgroup differences (chi-square ¼ 0.29; P ¼ .59; I 2 ¼ 0%).
Mortality
Six studies contributed to the analysis of mortality; no differences between the IGCS-based prophylaxis and the control group were found in both randomized (RR, 0.87; 95% CI, 0.55-1.38; P ¼ .55; I 2 ¼ 0%) and observational studies (RR, 0.97; 95% CI, 0.33-2.84; P ¼ .96; I 2 ¼ 0%), with findings consistent between these 2 subgroups (chi-square ¼ 0.05; P ¼ .83; I 2 ¼ 0%) ( Figure E2 ).
Sensitivity Analyses
Sensitivity analyses performed by removing each of the studies one at a time and repeating the calculations did not alter the direction or magnitude of the effect ( Figure E3 ). The estimates did not change after exclusion of studies with a high risk of bias, studies available as abstract only, and studies in which other than Food and Drug Administration-approved Collatamp (EUSA Pharma, Oxford, England) was used. The results also remained consistent when we excluded studies in which gentamicin sponge was premoistened quickly in saline before implantation. 
DISCUSSION
The incidence of SWI after heart surgery varies from 0.9% to 20.0% across the available literature. 24 In the present meta-analysis, it accounted for 3.82% in IGCS-treated patients and 3.98% in controls. The present report highlights the potential role of gentamicin sponge implantation as an SWI prophylaxis during cardiac surgery. Unlike previous reports, 25, 26 this is the first meta-analysis to also include observational studies. The main findings of the present meta-analysis are as follows: (1) IGCS is universally associated with an approximately 40% SWI risk reduction, with results consistent between randomized and observational data; (2) in the overall analyses, this reduction is sustained for separate single end points: DSWI, SSWI, and mediastinitis; (3) mortality was not influenced by IGCS; and (4) the benefit provided by the gentamicin sponge might be attenuated when BITA is harvested.
SWIPE-1 questioned for the first time the longestablished efficacy of gentamicin sponge implantation for SWI prophylaxis. 7 In a large 48-center study, the authors demonstrated no reduction of SWI with gentamicinimpregnated collagen sponges in patients undergoing cardiac surgery, thus showing results contradictory to those from previous randomized and observational data. The authors explained the between-study discrepancies by the potential of onsite monitoring and source data verification with central adjudication of outcomes by an independent blinded committee and the multicenter design, and therefore higher ethnic and regional variability, in turn associated with diverse bacterial pathogens distribution (6.3% of methicillin-resistant Staphylococcus aureus in the SWIPE-1 vs 0.0% in study by Friberg and colleagues 3, 27 ). The latter may be of lesser importance in light of increasing methicillin resistance across coagulase-negative staphylococci strains and the majority of the pathogens generally susceptible to gentamicin. Concern remains regarding the high percentage of Gram-negative G(À) strains in the US trial obtained from microbial swabs compared with the remaining studies (63% vs 0%-13%). This poses the question of when exactly the surgical site infection occurred because G(À) flora should not be present in the air of the operating room and do not generally reside on the skin of the chest as do G(þ) pathogens, and in particular coagulasenegative staphylococci. Therefore, it was argued 26, 28 that infections occurred postoperatively rather than in the perioperative period and to a lesser extent were dependent on the gentamicin prophylaxis. In a counter publication, Friberg and Bodin 21 listed the flaws of the SWIPE-1 design, with a failure to follow manufacturer-advised sponge implantation protocol as their strongest argument. The differences in outcomes in the 2 studies were attributed to a longer exposure of gentamicin sponge to saline solution soon before implantation, thus resulting in different concentrations of gentamicin sulphate in the collagenbased matrix. The importance of this phenomenon was further corroborated by Lovering and Sunderland, 29 who found in an in vitro study a mean loss of 6.7% of gentamicin concentration after 2 seconds of exposure to saline, increasing to 40.5% at 1 minute. Collagen sponge without gentamicin was further speculated to act as a culture medium and supported by the highest benefit of IGCS compared with placebo sponge in the study by Schimmer and colleagues. 16 Quick deployment of the sponge with or without conditional short-dipping in the water solution, just to enable easier handling, therefore seems to play an essential role in the SWI prophylaxis; however, to date no single randomized study has addressed this concern.
The majority of the studies published so far have shown that the use of IGCS may significantly reduce the incidence of infectious complications after cardiac surgery. The current article is the first to demonstrate the consistent infection risk reduction in both a randomized and observational subset of patients; this is of particular importance because randomized trials tend to enroll highly selected groups of patients, thus compromising real-world scenario analyses. With the exception of SWIPE-1, which enrolled high-risk patients undergoing cardiac surgery (diabetes, BMI >30 kg/m 2 , or both), all RCTs were conducted in a mostly elective setting with the percentage of diabetic persons ranging from 18.3% to 32.4% and average BMI ranging from 26 to 28 kg/m 2 . Our analysis demonstrated, apart from substantial reductions in DSWI and SSWI, a 33% significant (RR, 0.67; 95% CI, 0.49-0.92; P ¼ .01) mediastinitis risk reduction with IGCS.
Another important finding of the current meta-analysis is a positive linear correlation between the logRR of SWI and the percentage of patients receiving a BITA graft, indicating the lesser benefit provided by the IGCS in this population. These findings are in line with previous reports demonstrating BITA to be an independent risk predictor for DSWI 30, 31 ; however, indicating for the first time that in case of patients' elevated baseline risk (diabetes, high BMI, chronic obstructive pulmonary disease, renal dysfunction) and BITA harvest, IGCS alone might not prevent infectious complications to an extent provided when SITA is used. Another potentially preventive measure must be taken in such patients, such as meticulous pinpoint hemostasis, rigid sternum fixation, avoidance of excessive use of bone wax, strict aseptic technique, and, above all, skeletonization of the internal thoracic arteries should be strongly preferred rather than pedicled harvest. 32 We found no linear correlation between risk of SSWI alone and BITA harvesting; this finding might reflect the high potential of locally applied gentamicin to infiltrate the sternal fascia and subcutaneous tissue, unhindered by compromised blood circulation in the sternal region because of bilateral loss of the internal thoracic artery.
Gentamicin-collagen implants have been extensively tested outside the cardiothoracic surgery field and shown to decrease wound infections in other groups of patients undergoing surgical procedures, including open and endoscopic abdominal, vascular, and breast surgery. Reports are available on IGCS applied during surgical repair of pilonidal sinus, perianal abscess, inguinal hernia, and treatment of hidradenitis suppurativa.
E1-E19 In addition to gentamicin, other topical antibiotics have been tested in SWI prophylaxis with promising results, among them vancomycin and bacitracin. In a recent study by Lazar and colleagues, 33 patients undergoing cardiac surgery and treated with topical vancomycin applied as a slurry to the cut edges of the sternum were less likely to develop SSWI and DSWI (0% vs 1.6%, P < .0001 and 0% vs 0.7%, P ¼ .005, respectively) compared with a matched control group. Another study found a 6-fold reduction in the risk of mediastinitis after cardiac surgery in patients in whom bacitracin ointment was applied to the sternotomy incision after closure. 34 As for the cost-effectiveness, Speir and colleagues 35 report $62,773 of additive costs for patients developing SWI after coronary artery bypass grafting. In our institution, the average estimated cost increases approximately 5-fold from baseline, accounting for hospital stay, antibiotics, vacuum-assisted closure, and definitive surgical treatment 
Study Limitations
Several limitations to our meta-analysis should be acknowledged. First, the present analysis shares the limitations of the original studies included; therefore, the results were analyzed on the trial level and not on the patient level. Without individual patient data, we could not adjust for baseline risk factors and clinical characteristics. The criteria for patients' inclusion were broad across the studies, more closely reflecting current clinical practice, enrolling both high-risk and elective surgery cases. Potentially heterogeneous definitions of superficial wound infection might pose another limitation. Because of the substantial paucity of randomized data, observational data, both prospective and retrospective, also were included. As a consequence, the majority of the studies were retrospective in nature and thus are always subject to potential biases, that is, selection bias, with the surgeon implanting the gentamicin sponge in patients in whom the benefit with such prophylaxis was more probable (eg, obese or diabetic patients). On the other hand, observational studies were analyzed separately and using a random effect model; this approach ensures that any heterogeneity among the studies arising from differences in design, surgeon preferences, and patients' baseline clinical characteristics is identified. We noted no signs of inconsistency for the comparison between observational and randomized studies with the number of tests for subgroup differences. Despite these limitations, the consistency in magnitude and direction of the estimates and overall effect of IGCSs and the stability of the results in sensitivity analyses make the overall estimates justified and support the robustness of the conclusions.
CONCLUSIONS
IGCSs significantly reduce the risk of SWI after cardiac surgery, with evidence consistent in randomized and observational-level data. However, the extent of this benefit might be attenuated in patients receiving BITA grafts.
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